Literature DB >> 126094

A rapid and sensitive 125I-fibrin solid-phase fibrinolytic assay for plasmin.

L A Moroz, N J Gilmore.   

Abstract

125I-fibrinogen, adsorbed to polystyrene tubes at low ionic strength and treated with thrombin, serves as a substrate for a rapid, convenient, and sensitive test tube assay for plasmin and activators and inhibitors of this enzyme. 125I-labeled digestion products released from the 125I-fibrin-polystyrene matrix are readily separated and quantitated and behave, on gel permeation, in the same manner as plasmin-generated degradation products from an unlabeled conventional fibrin clot. The 125I-fibrin, in probable non-cross-linked form, is firmly bound to the polystyrene and is resistant to nonspecific release, with control (no enzyme) values equivalent to 15.2 ng +/- 1.2 (SD) fibrin (1% of the total bound 125I-fibrin). This fact permits consistent detection of lysis of 30-50 ng 125I-fibrin, which exceeds published sensitivities (1000-5000 ng) using 125I- or fluorochrome-labeled fibrin clots as substrate. The sensitivity for plasmin (0.2 mug/ml) is tenfold greater than that of the fibrin-plate method (2.0-2.5 mug/ml), while sensitivities for streptokinase and urokinase activation of plasmin are 0.02 U/ml and 0.04 CTA U/ml, respectively (sensitivity of fibrin-plate method, 0.5 U/ml for both). The method provides a reasonable analogue of the solid-phase nature of fibrin under physiologic conditions, and the ease of preparation of large batches of tubes makes the method suitable for large-scale screening of factors modulating the plasminogen-plasmin system.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 126094

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Interaction and complex-formation between the eosinophil cationic protein and alpha 2-macroglobulin.

Authors:  C G Peterson; P Venge
Journal:  Biochem J       Date:  1987-08-01       Impact factor: 3.857

2.  Studies of binding of prekallikrein and Factor XI to high molecular weight kininogen and its light chain.

Authors:  R E Thompson; R Mandle; A P Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

3.  Effect of phenoxymethylpenicillin, erythromycin, lymecycline and doxycycline upon the release of proteases from human leukocytes.

Authors:  S Engquist; C Lundberg; C Petterson
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

4.  Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.

Authors:  P Gresele; S Momi; M Berrettini; G G Nenci; H P Schwarz; N Semeraro; M Colucci
Journal:  J Clin Invest       Date:  1998-02-01       Impact factor: 14.808

5.  The role of leukocytes in the pathogenesis of fibrin deposition in bovine acute lung injury.

Authors:  B D Car; M M Suyemoto; N R Neilsen; D O Slauson
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

6.  Fibrin deposition and adaptive changes in glomerular procoagulant and fibrinolytic activities in rat renoprival nephropathy.

Authors:  P Ruedin; B Mougenot; D Ruedin; E Rondeau; J D Sraer; R Lacave; A Kanfer
Journal:  J Exp Pathol (Oxford)       Date:  1990-04

7.  Reversal of shortened platelet survival in rats by the antifibrinolytic agent, epsilon aminocaproic acid.

Authors:  P D Winocour; R L Kinlough-Rathbone; M Richardson; J F Mustard
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

8.  Intrapulmonary clotting and fibrinolysis during abdominal aortic aneurysm surgery.

Authors:  G A McLoughlin; G A Grindlinger; J Manny; C R Valeri; B Lipinski; J A Mannick; H B Hechtman
Journal:  Ann Surg       Date:  1979-11       Impact factor: 12.969

Review 9.  Development and Testing of Thrombolytics in Stroke.

Authors:  Dmitri Nikitin; Seungbum Choi; Jan Mican; Martin Toul; Wi-Sun Ryu; Jiri Damborsky; Robert Mikulik; Dong-Eog Kim
Journal:  J Stroke       Date:  2021-01-31       Impact factor: 6.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.